An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.
Inclusion Criteria:
Exclusion Criteria:
Birmingham, Alabama 35205, United States
Encinitas, California 92008, United States
Fort Myers, Florida 33901-8101, United States
St. Petersburg, Florida 33705, United States
St Louis, Missouri 63141, United States
Lincoln, Nebraska 68510, United States
Lebanon, New Hampshire 03756, United States
New York, New York 10032, United States
McAllen, Texas 78503, United States